John Lunger has served as our Chief Patient Supply Officer since August 2019 and is a member of our Executive Team. John leads the teams responsible for producing and delivering products to patients, accelerating supply execution, and optimizing the supply chain to be ready for commercialization. Prior to joining our Executive Team, he was Senior Vice President, Manufacturing and Supply Chain at Adaptimmune, having joined the Company in March of 2017. In this role, he was responsible for clinical manufacturing and global supply of Adaptimmune’s autologous T-cell therapy products.
Previously, John was Head of Supply Chain and Commercial Product Supply at Merrimack Pharmaceuticals where he led clinical and commercial supply chain as well as the cross functional supply team for Merrimack’s first commercial product launched in October of 2015. Earlier in his career, he held various senior manufacturing, operational, and strategy roles with VWR International, Pfizer, and Wyeth Pharmaceuticals. In his nearly 10 years with Wyeth he held a number of leadership positions, including operations and supply chain strategy, supply management, procurement and strategic sourcing, business systems implementation, generic pharmaceutical business management, and site operations management in a pharmaceutical manufacturing plant in Ireland. John began his career serving as a nuclear trained officer on a U.S. Navy submarine followed by strategic consulting with Accenture.
John holds a Bachelor of Science degree (with distinction) in Ocean Engineering from the US Naval Academy and an MBA in economics and operations management from the University of Chicago’s Booth School of Business.
What is John Lunger's net worth?
The estimated net worth of John Lunger is at least $3,136.05 as of August 1st, 2023. Mr. Lunger owns 4,718 shares of Adaptimmune Therapeutics stock worth more than $3,136 as of November 21st. This net worth estimate does not reflect any other assets that Mr. Lunger may own. Additionally, Mr. Lunger receives an annual salary of $645,910.00 as Insider at Adaptimmune Therapeutics. Learn More about John Lunger's net worth.
How old is John Lunger?
Mr. Lunger is currently 54 years old. There are 4 older executives and no younger executives at Adaptimmune Therapeutics. The oldest executive at Adaptimmune Therapeutics is Dr. Elliot Norry B.A., M.D., Chief Medical Officer, who is 60 years old. Learn More on John Lunger's age.
What is John Lunger's salary?
As the Insider of Adaptimmune Therapeutics plc, Mr. Lunger earns $645,910.00 per year. There are 4 executives that earn more than Mr. Lunger. The highest earning executive at Adaptimmune Therapeutics is Mr. Adrian G. Rawcliffe, CEO, Principal Accounting Officer & Director, who commands a salary of $1,060,000.00 per year. Learn More on John Lunger's salary.
How do I contact John Lunger?
Has John Lunger been buying or selling shares of Adaptimmune Therapeutics?
John Lunger has not been actively trading shares of Adaptimmune Therapeutics during the last ninety days. Most recently, John Lunger sold 3,096 shares of the business's stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $0.91, for a transaction totalling $2,817.36. Following the completion of the sale, the insider now directly owns 4,718 shares of the company's stock, valued at $4,293.38. Learn More on John Lunger's trading history.
Who are Adaptimmune Therapeutics' active insiders?
Are insiders buying or selling shares of Adaptimmune Therapeutics?
During the last year, insiders at the biotechnology company sold shares 7 times. They sold a total of 61,977 shares worth more than $53,507.07. The most recent insider tranaction occured on June, 18th when insider Cintia Piccina sold 24,531 shares worth more than $22,813.83. Insiders at Adaptimmune Therapeutics own 12.4% of the company.
Learn More about insider trades at Adaptimmune Therapeutics. Information on this page was last updated on 6/18/2024.
